Author Guidelines

Sections

1. SUBMISSION
2. AIMS AND SCOPE
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS
4. PREPARING THE SUBMISSION
5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS
6. AUTHOR LICENSING
7. PUBLICATION PROCESS AFTER ACCEPTANCE
8. POST PUBLICATION
9. EDITORIAL OFFICE CONTACT DETAILS

1. SUBMISSION

Authors should kindly note that submission implies (i) that the content has not been published previously, in any language, in whole or in part, except as a brief abstract in the proceedings of a scientific meeting or symposium; and (ii) that the manuscript is not currently under consideration for publication elsewhere.

New submissions should be made via the Research Exchange submission portal https://submission.wiley.com/journal/cep.  Should your manuscript proceed to the revision stage, you will be directed to make your revisions via the same submission portal. You may check the status of your submission at any time by logging on to submission.wiley.com and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact [email protected].

Free Format submission

Clinical and Experimental Pharmacology and Physiology now offers Free Format submission for a simplified and streamlined submission process.

2. AIMS AND SCOPE

Clinical and Experimental Pharmacology and Physiology provides a medium for the rapid online publication of original research papers, rapid communications, and technical papers on the results of clinical and experimental work in pharmacology and physiology. Reviews, research highlights and news/views are also published.

The journal aims to make a substantial contribution to effective and productive communication between scientists throughout the world who are working in these interrelated disciplines. Clinical and Experimental Pharmacology and Physiology has been endorsed by the High Blood Pressure Research Council of Australia (HBPRCA), the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Australian Physiological Society (AuPS).

Peer Review and Acceptance
The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Manuscripts are peer reviewed by at least two anonymous reviewers. A manuscript may be rejected without review, however, if the Editor-in-Chief deems it inappropriate for the journal. The content of the manuscripts will be held in strict confidence by the editors. The decision to accept or reject rests with the Editors. Where contributions are judged as acceptable for publication on the basis of content, the Editor and the Publisher reserve the right to modify manuscripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.

If authors are from the editorial board of Clinical and Experimental Pharmacology and Physiology including Editor-in-Chief, Senior Editors, Associate Editors, Society Editors, Editorial Board Members and Advisory Board Members, they will be excluded from the peer-review process and all editorial decisions related to the publication of this article.

New Pathways: Transferred and Expedited Peer Review. The Editors are able to offer expedited peer review for papers that have already been through the review process with a number of select journals. If you have an original article that has been found not to be acceptable for publication by one of a small number of journals on the basis of a perceived lack of priority rather than major flaws in scientific rigour, you may wish to consider using our 'New Pathways' review option. A full list of these journals, along with detailed instructions for submission and information about the expedited review of such manuscripts, can be found online. Articles should be submitted in their original form along with a copy of the decision letter from the journal. The decision letter should include at least two sets of reviewer comments. These manuscripts will then receive expedited review by the Editor.

Transparent Peer Review: This journal is participating in a pilot on Peer Review Transparency. By submitting to this journal and opting in this pilot, authors agree that the reviewer reports, their responses, and the editor’s decision letter will be linked from the published article to where they appear on Publons in the case that the article is accepted. Authors have the opportunity to opt out during submission, and reviewers may remain anonymous unless they would like to sign their report.

Subjects covered
Contributors are invited to submit manuscripts as Original Articles, Review, Technical Papers, Rapid Communications and Letters to the Editor. The content of these papers may be in any of the fields that are covered by the title Clinical and Experimental Pharmacology and Physiology, interpreted in the broadest sense. The journal particularly welcomes papers within the broad subject of translational medicine and has a policy of not publishing papers describing studies of the effects of impure natural substances. Experimental studies that provide new mechanistic insights are given priority over those that are largely descriptive.

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Editorial (by invitation only)
• Word Limit: 2000 words
• Abstract: No abstract
• References: Up to 10
• Description: Proposals for Editorial  may be submitted for consideration. An outline of the proposed Editorial Commentary should be submitted in the first instance rather than the full text.

Review
• Word limit: 6000 words, including Title Page, Abstract, Text, References and Tables
• Abstract: 250 words maximum
• References: Up to 120 Figures/tables: Maximum 8.
• Description: Reviews are comprehensive analyses of specific topics. Proposals for reviews may be submitted with an outline of the proposed paper, the abstract and the author’s publication list for initial consideration. Both solicited and unsolicited review articles will undergo peer review prior to acceptance.

Research Highlights 
• Word Limit: 3000 words, including Title Page, Abstract, Text, References and Tables
• Abstract: 250 words maximum
• References: Up to 80
• Figures/Tables: Maximum 4
• Description: Research Highlights focus on a particular topic and an editor is appointed to oversee the peer review process. The manuscripts are presented in the form of a mini-review. Original data may be included, but if so, sufficient detail on methods must be provided so that proper peer review can be accomplished. 

Original Article
• Word limit: 6000 words, including Title Page, Abstract, Text, References and Tables Abstract: 250 words maximum
• References: Up to 60
• Figures/tables: Maximum 8
• Description: Full-length reports of current research in any of the fields covered by the title Clinical and Experimental Pharmacology and Physiology, interpreted in the broadest sense. The text should be arranged as follows: Abstract, Introduction, Results, Discussion, Methods, Acknowledgements, References. Supporting information should be provided in a separate file.

New pathways: Transferred Peer Review. Please read the section 'New Pathways: Transferred Peer Review' above for information on submitting original articles along with reviews from selected other journals. More details on the CEPP New Pathways program can be found here.

Technical Note
• Word Limit: 6000 words, including Title Page, Abstract, Text, References and Tables
• Abstract: 250 words maximum
• References: Up to 60
• Figures/tables: Maximum 8
• Description: Technical Notes should focus on projects that did not yield publishable results but represent valuable information regarding new techniques or procudures, testing or critique of existing teachiques, protocols, and experimental or computational methods. These should be structured like Original Articles.

Rapid Communication
• Word limit: 3000 words (excluding references)
• Abstract: maximum 250 words
• Figures/ tables: 4 maximum
• References: 60 maximum
• Description: Rapid Communications report most important new findings and are given priority by the Editorial Office. The text should include Abstract, Introduction, Results, Discussion, Methods, Acknowledgements and References. Authors should indicate the reasons for Rapid publication.

Letter to the Editor
• Word limit: 1200 words
• Abstract: 120 words
• References: Up to 30
• Figures/ tables: 2 maximum
• Description: Letter to the Editor focus on the topics of short cutting edge research. Comments on papers recently published in CEPP will be welcomed. They should include a brief summary and key words, but no subheadings. Name, postal address, telephone, facsimile numbers and email addresses of the corresponding author should be given on the title page.

Letters to the Editor are not subjected to external peer review, but will be reviewed by at least one editor or editorial board member. Submissions may be edited for length, grammatical correctness, and journal style. Authors will be asked to approve editorial changes that alter the substance or tone of a letter or response. Letters that offer perspective on content already published in the Journal can use an arbitrary title, but a response from authors must cite the title of the first Letter: e.g. Response to [title of Letter]. This ensures that readers can track the line of discussion.

4. PREPARING THE SUBMISSION

Manuscript Format and Style

Manuscripts should follow the style of the Vancouver agreement detailed in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, as presented in JAMA 1997; 277: 927-34.

Spelling. The journal uses UK spelling and authors should follow the latest edition of the Oxford Concise English Dictionary.

Footnotes. Footnotes arising from the text must not be used.

Standard abbreviations. These should be used sparingly. They should be defined in the Summary and on the first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader.

Units of measurement.As far as possible, these should conform to the SI conventions, with the notable exception that blood pressures should be given in mmHg. It is strongly recommended that contributors consult the booklet Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. D. N. Baron), 1988, The Royal Society of Medicine Services, London. The recommendations outlined therein will be followed.

Methods of statistical analysis
The journal recommends that investigators seek the advice of a professional biostatistician in the design stage of their study, as well as during the stage of actual data analysis. Statistical methods used should be identified, with appropriate citation of statistical texts or articles that describe their use. Reasons for choosing particular methods of analysis, and for the number of experimental units, should be stated. The name and source of commercial statistical computer packages used should be identified. The statistical section should contain sufficient detail for the reader to have a clear idea about how the analysis was performed. The level of statistical significance (alpha) should be defined and it should be stated explicitly whether this refers to one- or two-sided probability. Nevertheless, exact P values should be given to a sensible number of significant figures (e.g. P = 0.01 rather than P = 0.0058). The risk of type 1 error (a false positive inference) should always be controlled. This requires the use of global statistical tests of significance where possible, particularly in experimental designs that involve repeated measurements in the same experimental units (humans, animals, tissues or cells). Multiple comparisons within a single experiment should only be made when this is absolutely necessary and, if so, P values should be conservatively corrected to control the risk of type 1 error. Two techniques that provide excellent control of the type 1 error rate are the 'false discovery rate' procedure (Curran-Everett D, Benos DJ. Guidelines for reporting statistics in journals published by the American Physiological Society. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004; 287: R247-9) and the Ryan-Holm stepdown Bonferroni procedure (Ludbrook J. Multiple comparison procedures updated. Clin. Exp. Pharmacol. Physiol. 1998; 25: 1032-7). Confidence intervals may be used in addition to P values.

Data should be expressed as mean (SD) when the intention is to indicate the degree of variability of the data around the mean value, and as mean ± SEM when the intention is to estimate the population mean from the sample data. In either case, the numbers of observations (n) should be stipulated. This allows the reader to calculate SD from SEM and vice versa. (For further reading, see Ludbrook J. Comments on journal guidelines for reporting statistics. Clin. Exp. Pharmacol. Physiol. 2005; 32: 324-6 (Letter). Detailed guidelines on the use and presentation of statistics in Clin. Exp. Pharmacol. Physiol. can be found online.

Chemical substances
These must be properly identified. Except for standard laboratory chemicals, the source of supply must be given. Drug nomenclature should follow the rules of the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification, published in various articles in Pharmacological Reviews. Proprietary names should be avoided unless the paper is concerned with a specific formulated product, in which case the nature of the formulation should be stated. Isotopically labelled chemicals should be identified by the atomic number and symbol of the isotope, its location in the molecule and the specific activity in standard (SI) units.

Receptors
For receptor types, nomenclature should also follow the conventions established by the IUPHAR Committee on Receptor Nomenclature and Drug Classification (International Union of Basic and Clinical Pharmacology), which are published in Pharmacological Reviews.

Parts of the Manuscript

Submissions via the new Research Exchange portal can be uploaded either as a single document (containing the main text, tables and figures), or with figures and tables provided as separate files. Should your manuscript reach revision stage, figures and tables must be provided as separate files. The main manuscript file can be submitted in Microsoft Word (.doc or .docx) formats.

Manuscripts should be presented in the following order: (i) Title Page, (ii) Abstract and keywords, (iii) Introduction, (iv) Results, (v) Discussion, (vi) Methods, (vii) Acknowledgements (including disclosure), (viii) References, (ix) tables (each table complete with title and footnotes), (x) figure legends and (xi) figure. Supporting Information should be supplied as a supplementary file.

The first page of the manuscript should contain the following information:

Title: The title should be as informative as possible but should avoid over-detailed information about the experimental procedures. Titles should not exceed 250 characters (including spaces).

Family name for each author, preceded by initial(s) or given name(s): That part of each family name which is to appear in indexes must be underlined.

Laboratory or Institute: The official name (in English) of each place in which the work reported in the manuscript was carried out should be given, together with the larger organization (if applicable), city, state (if applicable) and country.

Short title: This will be used as a running heading in the printed text; it must not exceed a total of 45 characters (including spaces) and should be as informative as possible within this limit. Abbreviations should be avoided if possible.

Author for correspondence: The name and full postal address, facsimile, telephone and email details of the corresponding author must be provided and clearly identified. All correspondence regarding the manuscripts, proofs and requests for reprints will be sent to this author, using the contact details provided.

Present addresses of authors: Should the addresses of other authors differ from that of the author for correspondence, this information should be provided and will be published.

Abstract and keywords
Abstract. This should commence on page two and consist of a continuous paragraph, describing the aim of the study, what was done, the main findings and the conclusions reached. A limit of 250 words applies to article abstracts, and 120 for Letters to the Editor.

Key words: These are required for indexing the content of the paper, and should, if possible, be selected from the US National Library of Medicine's Medical Subject Headings (MeSH) browser list. A maximum of 10 words or phrases should be sufficient. Key words should be arranged in alphabetical order.

References: Up to 60
Figures/tables: Maximum 8
Description: Technical Papers should be based mainly on the presentation of new techniques, or the testing or critique of existing techniques. These should be structured like Original Articles.

Introduction
This section should commence on a new page and contain a concise statement of the reason for doing the work, and should not contain a major statement about either the findings or the conclusions.

Results
The findings should be presented clearly with adequate reference to figures and tables. The text of Results and the information contained in figures and tables should complement one another; repetitive presentation of the same data should be avoided. Material appropriate to Discussion should not be included in Results. However, brief comments on minor points are acceptable if they help to consolidate the new information being presented or if they assist the reader to follow the progression of ideas in moving from one set of data to another.

Discussion
This should not be a mere reiteration of the Results. It should deal with the relationship of the new information given in Results to the corpus of knowledge in that field, and should be pertinent to the data presented. The main conclusions should be incorporated in the final paragraph.

Methods
Sufficient information should be given to permit the work to be repeated in other clinics or laboratories.

Acknowledgements
The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors’ industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Thanks to anonymous reviewers are not appropriate.

References
List all sources in the reference list sequentially as they occur in the text. In text citations should follow the Vancouver style, i.e. numbered and ordered numerically in the reference list. All citations mentioned in the text, tables or figures must be listed in the reference list. If cited in tables or figure legends, number according to the first identification of the table or figure in the text. Titles of journals should be abbreviated according to the style used in Index Medicus. Please note that authors are responsible for the accuracy of the references.

Journal article:
2. Thomsen SF, Ulrik CS, Kyvik KO, Larsen K, Skadhauge LR, Steffensen I, Backer V. The incidence of asthma in young adults. Chest. 2005;127:1928-34.

Book edition:
2. Storm BC. Asthma. In: Thompson VC, Olson O, editors. Pulmonary Pathophysiology. Baltimore: Williams & Wilkins; 1990. p. 27-42.

Tables
should be numbered consecutively in Arabic numerals. Each table should be presented on a separate page with a comprehensive but concise legend above the table. Tables should be double-spaced and vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations should be defined in footnotes. Footnote symbols: †, ‡, § should be used (in that order) and *, **, *** should be reserved for P values. The table and its legend/footnotes should be understandable without reference to the text.

Figures
All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Magnifications should be indicated using a scale bar on the illustration.

Cover Image Submissions  

This journal accepts artwork submissions for Cover Images. This is an optional service you can use to help increase article exposure and showcase your research. For more information, including artwork guidelines, pricing, and submission details, please visit the Journal Cover Image page.  

Size. Figures will be greatly reduced in size for publication. Fonts must therefore be large and consistent and lines should be relatively thick. Authors should prepare figures to fit within the column (84 mm), or the full text width (176 mm).

Resolution. Figures must be supplied as high resolution saved as .eps or .tif.

Halftone figures: 300 dpi (dots per inch)
Colour figures: 300 dpi saved as CMYK
Figures containing text: 400 dpi
Line figures: 1000 dpi Color figures.

Files should be set up as CMYK (cyan, magenta, yellow, black) and not as RGB (red, green, blue) so that colors as they appear on screen will be a closer representation of how they will print in the journal. Figures are published in colour in the journal free of charge.

Figure legends
Type figure legends on a separate page. Legends should be concise but comprehensive. The figure and legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Further information can be obtained at: The CEPP Guidelines for Preparation of Figures: and Wiley's guidelines for preparation of figures.

Equations
Equations should be numbered sequentially with Arabic numerals; these should be ranged right in parentheses. All variables should appear in italics. Use the simplest possible form for all mathematical symbols.

Graphical abstracts

Clinical and Experimental Pharmacology and Physiology publishes graphical abstracts for research articles and review articles, displayed online in graphical form with a brief abstract, in addition to the up to 250 word abstract above. The online table of contents will display a schematic figure to convey the core message of your paper, alongside a short abstract highlighting the major findings of the paper. Authors should submit a new and stand-alone image, or designate an image already included in the paper. Your short abstract should consist of 2-3 sentences summarizing the essence of the paper. Graphical abstract entries should be submitted to Scholar One in one of the generic file formats and uploaded as ‘Graphical Abstract’ during the initial manuscript submission process. The image should fit within the dimensions of 50mm x 60mm, and be fully legible at this size.

Supporting Information

Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc. Click here for Wiley’s FAQs on supporting information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

Wiley Author Resources

Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.

Article Preparation Support: Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.


SUMMARY OF SUBMISSION REQUIREMENTS

A cover letter should be included in the ‘Cover Letter Field’ of the ScholarOne system. The text can be entered directly into the field or uploaded as a file. The covering letter must contain:

• An acknowledgment that all authors have contributed significantly and that all authors are in agreement with the content of the manuscript.

• In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author’s contribution to the paper is to be quantified.

• Authors must also state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki (as revised in Brazil in 2013).

• Authors must declare any financial support or relationships that may pose conflict of interest, for more detail refer to the section ‘Disclosure’ above.

Cover Letters and Conflict of Interest statements may be provided as separate files, included in the manuscript, or provided as free text in the submission system. A statement of funding (including grant numbers, if applicable) should be included in the “Acknowledgements” section of your manuscript.

Two Word-files need to be included upon submission: A title page file and a main text file that includes all parts of the text in the sequence indicated in the section 'Parts of the manuscript', including tables and figure legends but excluding figures which should be supplied separately.

The main text file should be prepared using Microsoft Word, doubled-spaced. All pages should be numbered consecutively in the top right-hand corner, beginning with the first page of the main text file.

Each figure should be supplied as a separate file, with the figure number incorporated in the file name. For submission, low-resolution figures saved as .jpg or .bmp files should be uploaded, for ease of transmission during the review process. Upon acceptance of the article, high-resolution figures (at least 300 d.p.i.) saved as .eps or .tif files will be required.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Data Sharing and Data Accessibility

The journal requires authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.

Use of Human and/or animal subjects

Investigations in human subjects must conform to the International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS/WHO). Consent must be obtained from each patient or subject after full explanation of the purpose, nature and risks of all procedures used, and the fact that such consent has been given should be recorded in the paper. Patient anonymity should be observed.

Experiments using animals must adhere to internationally accepted guidelines for the use of animals in research (e.g. CIOMS Guidelines) and the highest acceptable standard of ethical practice. Currently, these are the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. The Code is obtainable from the Secretary, NHMRC, PO Box 9848. Canberra, ACT 2601 Australia.

The alternative is to use the CIOMS Guidelines. The purpose of the experiments must have been to obtain significant scientific information relevant to humans or other animals. Authors must declare, either in a covering letter or in the paper itself, whether or not prior approval for experiments was obtained from an animal experimentation ethics committee, animal care and use committee, equivalent committee or relevant body in the country of question. The name of the committee or relevant body must be included. Papers from countries where such committees are not established, or if such evidence is not provided, must conform to the relevant Australian Guidelines. Currently these are Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.

Anaesthetic, analgesic or other measures taken to reduce or abolish any pain or discomfort must be detailed. If death or serious injury is used as an experimental end-point, the paper must indicate why such end-points were essential. Neuromuscular blocking agents must not have been used without appropriate general anaesthesia, except in animals in which sensory awareness had been eliminated. Techniques and procedures that minimize the use of live animals must have been adopted where feasible and appropriate. The statistical methods should have ensured the use of the minimum number of animals compatible with valid experimentation. Clinical and Experimental Pharmacology and Physiology retains the right to reject any manuscript on the basis of unethical conduct of either human or animal studies.

Authorship and Acknowledgements

The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria: i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; ii) Drafting the work or revising it critically for important intellectual content; iii) Final approval of the version to be published; and iv) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.

Disclosure

Authors should declare any financial support or relationships that may pose a conflict of interest in the Covering Letter and in the manuscript under acknowledgements. If there is nothing to declare, a sentence should be included stating so.

Clinical Trials Registry

Registration in a public trials registry at or before the onset of patient enrolment is required. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we request registration by April 1, 2006. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as studies on pharmacokinetics or major toxicity (e.g. phase 1 trials), are exempt. We do not advocate one particular registry. The registry should meet the following minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).

Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine; (2) the International Standard Randomized Controlled Trial Number Registry; (3) the Australian Clinical Trials Registry; (4) the Chinese Clinical Trials Register; and (5) the Clinical Trials Registry - India; (6) University Hospital Medical Information Network (UMIN).

Randomized Control Trials

Reporting of randomized controlled trials should follow the guidelines of the Consort Statement.

Publication Ethics

This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read the Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found at authorservices.wiley.com/ethics-guidelines/index.html.

6. AUTHOR LICENSING

If a paper is accepted for publication, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.

Authors may choose to publish under the terms of the journal’s standard copyright agreement, or Open Access under the terms of a Creative Commons License.

General information regarding licensing and copyright is available here. To review the Creative Commons License options offered under Open Access, please click here. (Note that certain funders mandate a particular type of CC license be used; to check this please click here.)

Self-Archiving Definitions and Policies: Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click here for more detailed information about self-archiving definitions and policies.

Open Access fees: Authors who choose to publish using Open Access will be charged a fee. For more information on this journal’s APCs, please see the Open Access page.

Funder Open Access: Please click here for more information on Wiley’s compliance with specific Funder Open Access Policies.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted Article Received in Production

When an accepted article is received by Wiley's production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point.

Proofing

Authors will receive an e-mail notification with a link and instructions for accessing HTML page proofs online. Page proofs should be carefully proofread for any copyediting or typesetting errors. Online guidelines are provided within the system. No special software is required, all common browsers are supported. Authors should also make sure that any renumbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures. Proofs must be returned within 48 hours of receipt of the email. Return of proofs via e-mail is possible in the event that the online system cannot be used or accessed.

Continuous Publication

Under a Continuous Publication model used at Wiley, journal articles are published directly into an online issue with their final citations as soon as they are ready. There is no issue curation and no issue pagination; articles publish when they have completed production and are not held for upcoming issues. The ability to publish an article online before its issue is completed provides faster publishing of articles with final citation details for the academic community.

8. POST PUBLICATION

Access and Sharing

When the article is published online: 

  • The author receives an email alert (if requested).
  • The link to the published article can be shared through social media.
  • The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
  • The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.

Print copies of the article can now be ordered (instructions are sent at proofing stage or email www.sheridan.com/wiley/eoc)

To find out how to best promote an article, click here.

Article Promotion Support

Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

Measuring the Impact of an Article

Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.

9. EDITORIAL OFFICE CONTACT DETAILS

Inquiries regarding manuscripts and peer review should be emailed to:

Editorial Office: [email protected]